Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Zynex ( (ZYXI) ) has shared an update.
Zynex, Inc. announced the appointment of Steven Dyson as Chief Executive Officer, effective August 18, 2025, succeeding Thomas Sandgaard who will continue as Chairman of the Board. Dyson, with over 25 years of experience in healthcare investment and medical technology, aims to lead Zynex towards a stronger growth trajectory, leveraging his extensive background in the sector.
The most recent analyst rating on (ZYXI) stock is a Buy with a $16.00 price target. To see the full list of analyst forecasts on Zynex stock, see the ZYXI Stock Forecast page.
Spark’s Take on ZYXI Stock
According to Spark, TipRanks’ AI Analyst, ZYXI is a Neutral.
Zynex’s overall stock score is heavily impacted by its financial difficulties, which are the most significant factor. Despite some technical and strategic positives, the company’s financial health and valuation concerns dominate, requiring critical focus on revenue growth and cost management for improvement.
To see Spark’s full report on ZYXI stock, click here.
More about Zynex
Zynex, founded in 1996, is a medical technology company that develops, manufactures, markets, and sells non-invasive medical devices for pain management, rehabilitation, and patient monitoring systems for use in hospitals.
Average Trading Volume: 235,677
Technical Sentiment Signal: Sell
Current Market Cap: $80.44M
Learn more about ZYXI stock on TipRanks’ Stock Analysis page.